Are you a medical device manufacturer working on digital therapeutics, remote monitoring tools, or AI-enabled care solutions for chronic disease management? If your innovation is outcome-based and driven by real-world data, you should pay close attention to the U.S. FDA’s Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program.
Launched in December 2025 by the U.S. Food and Drug Administration’s (US FDA’s) Center for Devices and Radiological Health (CDRH), TEMPO is designed to expand patient access to certain digital health technologies while maintaining regulatory oversight and safety standards.
The initiative aligns with the Centers for Medicare & Medicaid Services (CMS) Innovation Center’s ACCESS Model, which focuses on technology-enabled care for chronic disease management.
What TEMPO Covers?
The TEMPO pilot focuses on digital health devices supporting chronic disease management in four key areas:
- Cardio-kidney-metabolic conditions
- Musculoskeletal (MSK) conditions
- Behavioral health conditions
FDA began accepting statements of interest from manufacturers in January 2026 and plans to select a limited number of participants for the pilot.
Why TEMPO Matters?
TEMPO introduces a risk-based regulatory approach that allows certain digital health devices to be used in real-world care environments while manufacturers collect structured real-world data (RWD).
Under this pilot:
- Manufacturers may request FDA enforcement discretion for certain regulatory requirements, such as premarket authorization.
- Real-world performance data can be collected and shared with the FDA.
- This evidence may later support future marketing submissions and regulatory decisions.
Technologies That May Benefit
TEMPO could significantly impact companies developing:
- Software as a Medical Device (SaMD)
- Remote patient monitoring solutions
- AI-enabled clinical decision support tools
- Digital therapeutics
By enabling early real-world deployment under regulatory supervision, TEMPO could shorten the time needed to demonstrate clinical value and patient outcomes.
What Manufacturers Should Prepare For
Participation in TEMPO does not reduce regulatory expectations. Instead, it shifts focus toward continuous real-world evidence generation. Companies should be prepared for rigorous evaluation of:
- Cybersecurity and data protection
- Usability and human-factor design
- Integration into clinical workflows
- Quality and reliability of real-world data
Manufacturers considering participation should assess whether their intended use, risk profile, and evidence generation strategy align with the program’s clinical focus areas.
Regulatory Strategy Matters
For innovators in digital health, TEMPO signals a broader shift in regulatory thinking. Programs that combine regulatory flexibility with outcome-based payment models are likely to reward technologies that demonstrate measurable patient benefit in real-world settings.
Organizations investing early in, regulatory expertise, evidence generation strategies, and compliance-by-design will be better positioned as programs like TEMPO evolve into future regulatory frameworks. Stay tuned for more regulatory insights.